Partner

Explore A Novel Platform

Genlumina offers pharmaceutical partners an indication-specific option to partner on a first-in-class light-activated oncology platform, without upfront capital expenditure or clinical development obligations.

Our model enables early strategic alignment while allowing partners to defer investment until preclinical value has been demonstrated.

How the Option Model Works

For each oncology indication, Genlumina offers a first-right-of-choice option that provides:

Exclusive access to a defined preclinical data package
Priority negotiation rights for licensing or co-development
A fixed evaluation window following data release

Until the option is exercised, partners have no obligation to fund research, clinical studies, or infrastructure.

Addressing Drug Resistance

Genlumina’s payload acts independently of classical resistance pathways.

Because cytotoxicity is:

light-dependent
nucleus-localized
mechanistically distinct from ADC warheads

the platform provides a potential solution for tumors that have developed resistance to existing therapies.

Lead Program

Light-Activated Peptide Drug Conjugate (PDC for CRC)

Our lead indication for Colorectal Cancer (CRC) is based on a locally administered, biodegradable peptide-drug conjugate (PDC), designed for precision targeting and controlled activation.

Key characteristics:

Targeting: Uses existing peptides or antibodies without the (chemo) payload.
Payload: Our proprietary light-activated drug (silver-based nano-cluster) with a customizable linker to existing targeting antibodies or peptides.
Activation: Triggered by spatially controlled light within a defined time window
Mechanism of Action: Upon light activation, the DNA packaging is transiently opened, enabling the payload to induce a localized spike from the silver that irreversibly disables tumor cell replication
Clearance: Our drug is biodegradable and locally confined, minimizing systemic exposure

Platform Compatibility

Genlumina’s technology is designed as a plug-and-play payload:

Compatible with existing antibodies and peptides
Applicable across multiple solid tumor indications
Enables rapid expansion without re-inventing targeting biology

Each indication can be partnered independently under a separate option.

Preclinical Data & Development

Genlumina is generating robust preclinical data across:

In vitro tumor models
In vivo mouse studies
Biodistribution and pharmacokinetics
Light-dependent efficacy and safety

Early engagement allows partners to:

Review data as it matures
Shape downstream clinical strategy
Accelerate decision-making post-preclinical phase.

Regulatory Perspective

Given its novel mechanism of action, local activation, and potential to address unmet medical need, Genlumina’s platform may be suitable for early regulatory engagement, including scientific advice and accelerated development pathways, subject to regulatory assessment.

Partner With Us

Genlumina invites pharmaceutical partners to engage early through an indication-specific option model — securing priority access to a differentiated oncology asset while deferring financial commitment until value is demonstrated.

Or discover how you can be parter in other ways:

Medical Specialists – Key Opinion Leaders

Together, we proof it is clinically relevant in your area of expertise that a cell precision treatment is offering hope and a new perspective for patients.

We provide proof-of-principle studies, grant support, and co-publication opportunities, forming a foundation for therapies that deliver both precision and effectiveness.

Targeting Therapeutic Partners

Together, we link our drug as payload to existing targeting mechanisms (Antibody Drug Conjugates/Peptide Drug Conjugates) that target specific types of cancer and can be reached with light.

We create an oppurtunity to join forces with researchers in the field of targeting therapeutics. This way a valuable biomarker becomes an effective therapy too.

MedTech Imaging Companies

Together, we combine our light-activated drug with your (extended) imaging systems, allowing hospitals and clinics to deliver precision treatments without requiring extensive equipment changes.

We provide a valuable enhancement for imaging platforms, helping healthcare providers expand their treatment capabilities with minimal disruption.

VC / Pharmaceutical Companies

Together, we can advance GenLumina’s technology to clinical trials, leveraging our safety and efficacy to develop a treatment that complements and enhances existing oncology treatments.

we support pharmaceutical partners through regulatory milestones, enabling an innovative addition to your oncology pipeline that has the potential to create significant patient impact.